Contents

CX-546

Chemical compound

CX-546

Clinical data
Other names	CX-546
Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name 2,3-dihydro-1,4-benzodioxin-7-yl-(1-piperidyl)methanone
CAS Number	215923-54-9 Y
PubChem CID	2890
IUPHAR/BPS	4166
ChemSpider	2787 N
UNII	PV6YEC8983
CompTox Dashboard (EPA)	DTXSID70175951
Chemical and physical data
Formula	C14H17NO3
Molar mass	247.294 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1CCN(CC1)C(=O)C2=CC3=C(C=C2)OCCO3
InChI InChI=1S/C14H17NO3/c16-14(15-6-2-1-3-7-15)11-4-5-12-13(10-11)18-9-8-17-12/h4-5,10H,1-3,6-9H2 N Key:LJUNPHMOGNFFOS-UHFFFAOYSA-N N
NY (what is this?)  (verify)

CX-546 is an ampakine drug developed by Cortex Pharmaceuticals.

It has been proposed as a treatment for schizophrenia.^[1] CX-546 was the second drug of note to come out of the Cortex research program, after CX-516, but while it was an improvement over its predecessor in some respects, it still has problems with limited oral bioavailability.

However, CX-546 still represented a significant advance that led on to the development of newer compounds such as CX-614 and CX-717 with superior properties over the earlier drugs. CX-546 itself has been investigated for other applications, and most notably has been found to show significant efficacy in reversing the respiratory depression produced by sedative drugs such as opioids and barbiturates.^[2]

No effective respiratory stimulants are currently marketed for this application, with CX-546 being only the third drug discovered (after BIMU-8 and BW373U86) that effectively relieves the respiratory depression induced by fentanyl without reducing the analgesic effects. CX-546 could be developed for this purpose, although it is more likely that Cortex will use newer and more potent analogues such as CX-1739 or CX-1763, which are likely to be more suitable for commercial development.^{[citation needed]}

See also[edit]

• AMPA receptor positive allosteric modulator

References[edit]